Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Jing, Yu  [Clear All Filters]
2014
Luo L, Zhang L, Cai B, Li H, Huang W, Jing Y, Zhu H, Zhao Y, Bo J, Wang Q, et al. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. Ann Transplant. 2014;19:6-12.
Jing Y, Chen H, Liu M, Zhou M, Guo Y, Gao C, Wang Q, Li H, Zhao Y, Bo J, et al. Susceptibility Of Ph-Positive All To Tki Therapy Associated With Bcr-Abl Rearrangement Patterns: A Retrospective Analysis. PLoS One. 2014;9(11):e110431.
2015
Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, Ma C, Ma X, Yao Y, Zhou L, et al. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS One. 2015;10(7):e0132620.
2019
Xu Q, Li Y, Jing Y, Lv N, Wang L, Li Y, Yu L. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer. 2019.
2022
Wang J, Jiang H, Jing Y, Su L, Liu D, Zhou D, Wang J, Liu H, Ruan GRui, Gao S, et al. Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. Br J Haematol. 2022.
2023
Yang S, Zhang X, Gale RPeter, Du X, Chen C-Y, Weng J-Y, Huang J, Li F, Zeng Y, Xiao Z, et al. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
Zhang R, Xin R, Dou L-P, Jing Y. [Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(6):1910-1915.
Liu Y, Li Y, Zhang R, Yu Z, Jing Y. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Front Immunol. 2023;14:1269163.